Skip to main content
SpringerLink
Log in

β-Blocker treatment of chronic heart failure with special regard to Carvedilol

  • Conference paper
Heart rate as a determinant of cardiac function

  • 170 Accesses

Abstract

Congestive heart failure is a major public health problem in most Western countries. In the United States, approximately three million people suffer from heart failure, 10 % of whom are admitted to a hospital each year (57). Although in recent decades considerable changes in medical therapy have been achieved, especially by angiotensin converting enzyme (ACE) inhibitors (19, 58), mortality of heart failure still remains very high. In patients of New York Heart Association (NYHA) functional class II there is a mortality of about 10 % (2). In order to improve this poor prognosis, additional pharmacological interventions to counteract the pathophysiological changes occurring in heart failure are still important.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersson B, Hamm C, Persson S et al. (1994) Improved exercise hemodynamic status in dilated cardiomyopathy after beta-blockade treatment. J Am Coll Cardiol 23: 1397–1404

    Article  PubMed  CAS  Google Scholar 

  2. Australia-New Zealand Heart Failure Research Collaborative Group (1995) Effects of Carvedilol, a vasodila-tor-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92: 212–218

    Google Scholar 

  3. Australia-New Zealand Heart Failure Research Collaborative Group (1997) Randomized, placebo-controlled trial of Carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 349: 375–380

    Article  Google Scholar 

  4. Awan NA, Needham KE, Evenson MK et al. (1981) Therapeutic application of prazosin in chronic refractory congestive heart failure: tolerance and “tachyphylaxis” in perspective. Am J Med 71: 153–160

    Article  PubMed  CAS  Google Scholar 

  5. Belch JJF, Bridges AB, Scott N, Chopra M (1991) Oxygen free radicals in congestive heart failure. Br Heart J 65: 245–248

    Article  PubMed  CAS  Google Scholar 

  6. Böhm M, Deutsch HJ, Hartmann D, La Rosée K, Stäblein A (1997) Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 30: 992–996

    Article  PubMed  Google Scholar 

  7. Böhm M, Gierschik P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, Erdmann E (1990) Increase of Gia in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82: 1249–1265

    Article  PubMed  Google Scholar 

  8. Bolli R (1990) Mechanisms of myocardial stunning. Circulation 82: 723–738

    Article  PubMed  CAS  Google Scholar 

  9. Bristow MR, Ginsburg R, Minobe W, Cubiciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DE, Stinson EB (1982) Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med 307: 205–211

    Article  PubMed  CAS  Google Scholar 

  10. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators (Comment). Circulation 94: 2807–2816

    PubMed  CAS  Google Scholar 

  11. Bristow MR, O’Connel JB, Gilbert EM et al. (1994) Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 89: 1632–1642

    PubMed  CAS  Google Scholar 

  12. CIBIS II-Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 353: 9–13

    Article  Google Scholar 

  13. CIBIS Investigators and Committees (1994) A randomized trial of β-blockade in heart failure. The Cardiac Insufficienty Bisoprolol Study (CIBIS). Circulation 90: 1765–1773

    Google Scholar 

  14. Cleland JGF, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F (1996) Beta-blocking agents in heart failure-should they be used and how? Eur Heart J 17: 1629–1639

    PubMed  CAS  Google Scholar 

  15. Cohn JN (1994) Vasodilators in heart failure: conclusions from V-HeFT II and rationale for V-HeFT III. Drugs 47 (suppl 4): 47–58

    Article  PubMed  Google Scholar 

  16. Cohn J, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinal V et al. (1997) Safety and efficacy of Carvedilol in severe chronic heart failure. J Card Failure 3: 173–179

    Article  CAS  Google Scholar 

  17. Cohn JN, Levine TB, Olivan MT, Gerberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 : 819–823

    Article  PubMed  CAS  Google Scholar 

  18. Colucci WS, Packer M, Bristow MR, Cohn J, Fowler MB, Gilbert EM et al. (1996) Carvedilol inhibits clinical progression in patients with mild heart failure. Circulation 94: 2800–2806

    PubMed  CAS  Google Scholar 

  19. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435

    Article  Google Scholar 

  20. Cruickshank JM, Neil-Dwyer G, Degaute JP et al. (1987) Reduction of stress/catecholamine-induced cardiac necrosis by betal-selective blockade. Lancet 1: 585–589

    Article  Google Scholar 

  21. The Digitalis Investigation Group (DIG) (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (8): 525–533

    Article  Google Scholar 

  22. Doughty RN, Whalley GA, Gamble G et al. on behalf of the Australia-New Zealand Heart Failure Research Collaborative Group (1997) Left ventricular remodeling with Carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 29: 1060–1066

    Article  Google Scholar 

  23. Eichhorn EJ, Bedotto JB, Malloy CR et al. (1990) Effects of β-adrenergic receptor blockade on myocardial function and energetics in congestive heart failure. Circulation 82: 473–483

    Article  PubMed  CAS  Google Scholar 

  24. Feldman MD, Alderman JD, Aroesty JM, Royal HD, Ferguson JJ, Owen RM, Grossman W, McKay RG (1988) Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in patients with dilated cardiomyopathy. J Clin Invest 82: 1661–1669

    Article  PubMed  CAS  Google Scholar 

  25. Ferro G, Duilio C, Spinelli L et al. (1991) Effects of beta-blockade on the relation between heart rate and ventricular diastolic perfusion time during exercise in systemic hypertension. Am J Cardiol 68: 1101–1103

    Article  PubMed  CAS  Google Scholar 

  26. Fisher ML, Gottlieb SS, Plotnick G et al. (1994) Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 23: 943–950

    Article  PubMed  CAS  Google Scholar 

  27. Flesch M, Maack C, Cremers B, Bäumer AT, Südkamp M, Böhm M (1999) Effect of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation 100: 346–353

    PubMed  CAS  Google Scholar 

  28. Gage J, Rutman H, Lucido D, Le Jemtel TH (1986) Additive effects of Dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74: 367–373

    Article  PubMed  CAS  Google Scholar 

  29. Gaudron P, Eilles C, Kugler I, Ertl G (1993) Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 87: 755–763

    PubMed  CAS  Google Scholar 

  30. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M et al. (1996) Comparative hemodynamic, left ventricular functional and antiadrenergic effects of chronic treatment with metoprolol versus Carvedilol in the failing heart. Circulation 94: 2817–2825

    PubMed  CAS  Google Scholar 

  31. Gilbert EM, Anderson JL, Deitchman D et al. (1990) Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am. J. Med. 88: 223–229

    Article  PubMed  CAS  Google Scholar 

  32. Gilbert EM, Olsen SL, Renlund DG, Bristow MR (1993) Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 71: 23C-29C

    Article  PubMed  CAS  Google Scholar 

  33. Hall SA, Cigarroa CG, Marcoux L, Risser RC et al. (1995) Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure trearted with beta-adrenergic blockade. J Am Coll Cardiol 25: 1154–6131

    Article  PubMed  CAS  Google Scholar 

  34. Hammermeister KE, De Rouen TA, Dodge HT (1979) Variables predictive of survival in patients with coronary disease: selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic and quantitative angiographic evaluations. Circulation 59: 421–430

    PubMed  CAS  Google Scholar 

  35. Hash TW, Prisant LM (1997) β-blocker use in systolic heart failure and dilated cardiomyopathy. J Am Coll Cardiol 37: 7–19

    Google Scholar 

  36. Hausdorff WP, Caron MG, Lefkowitz RJ (1990) Turning off the signal: desensitization of β-adrenergic receptor function. FASEB J 4: 2881–2889

    PubMed  CAS  Google Scholar 

  37. Heilbrunn SM, Shah P, Bristow MR, Valantine HA et al. (1989) Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79: 483–490

    Article  PubMed  CAS  Google Scholar 

  38. Imperato-McGinley J, Gautier T, Ehlers K et al. (1987) Reversibility of catecholamine-induced dilated cardiomyopathy in a child with pheochromocytoma. N Engl J Med 316: 793–797

    Article  PubMed  CAS  Google Scholar 

  39. Kukin ML, Kalman J, Mannino M, Freudenberger R et al. (1996) Combined alpha-beta-blockade (doxazosin and metoprolol) compared with beta-blockade alone in chronic congestive heart failure. Am J Cardiol 77: 486–491

    Article  PubMed  CAS  Google Scholar 

  40. Lahiri A, Rodrigues EA, Al-Khawaja I et al. (1987) Effect of a new vasodilating beta-blocking drug, Carvedilol, on left ventricular function in stable angina-pectoris. Am J Cardiol 59: 769–774

    Article  PubMed  CAS  Google Scholar 

  41. Lipicky RJ, Packer M (1993) Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol 22 (suppl A): 179A–184A

    Article  PubMed  CAS  Google Scholar 

  42. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001–2007

    Article  Google Scholar 

  43. Metra M, Nardi M, Giubbini R (1994) Effects of short- and long-term Carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 24: 1678–1687

    Article  PubMed  CAS  Google Scholar 

  44. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR (1992) Altered myocardial force-frequency relation in human heart failure. Circulation 85: 1743–1750

    PubMed  CAS  Google Scholar 

  45. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FE, Hajjar RJ, Schmidt U, Semigran MJ, Dee GW, Khaw BA (1996) Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335: 1182–1189

    Article  PubMed  CAS  Google Scholar 

  46. Nicholas G, Oakley C, Pouleur H et al. (1990) Xamoterol in severe heart failure. Lancet 336: 1–6

    Article  Google Scholar 

  47. Ohlstein EH, Douglas SA, Sung C-P et al. (1993) Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration and neointimal formation following vascular injury. Proc Natl Acad Sci USA 90: 6189–6193

    Article  PubMed  CAS  Google Scholar 

  48. Olivetti G, Abbi R, Quaini F Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski W, Reed JC, Anversa P (1997) Apoptosis in the failing human heart. N Engl J Med 336: 1131–1141

    Article  PubMed  CAS  Google Scholar 

  49. Packer M, Arver JR, Rodeheffer RJ, Ivanhoe RJ et al. for the PROMISE Study Research Group (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468–1475

    Article  PubMed  CAS  Google Scholar 

  50. Packer M, Bristow MR, Cohn JN et al. for the US Carvedilol study group (1996) The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349–1355

    Article  Google Scholar 

  51. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS et al. for the PRECISE Study Group (1996) Double-blind, placebo controlled study of the effects of Carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 94: 2793–2799

    Google Scholar 

  52. Parmershwar J, Shackel MM, Richardson A, Poole-Wilson PA, Sutton GC (1992) Prevalence of heart failure in three general practices in north west London. Br J General Pract 42: 287–289

    Google Scholar 

  53. Pfeffer MA, Stevenson LW (1996) β-adrenergic blockers and survival in heart failure. N Engl J Med 334: 1396–1397

    Google Scholar 

  54. Schwartz A, Lindenmayer GE, Harigaya S (1968) Respiratory control and calcium transport in heart mitochondria from the cardiomyopathic hamster. Trans N Y Acad Sci 30 (Suppl 2): 951

    PubMed  CAS  Google Scholar 

  55. Sharpe N, Murphy J, Smith H, Hannan S (1988) Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 255–259

    Google Scholar 

  56. Sigmund M, Jakob H, Becker H (1996) Effects of metoprolol on myocardial β-adrenoceptors and Gia-pro-teins in patients with congestive heart failure. Eur J Clin Pharmacol 51: 127–132

    Article  PubMed  CAS  Google Scholar 

  57. Smith WM (1985) Epidemiology of congestive heart failure. Am J Cardiol 55: 3–8A

    Article  Google Scholar 

  58. The SOLVD Investigators (1991) Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293–302

    Article  Google Scholar 

  59. Swedberg K (1994) Exercise testing in heart failure: a critical review. Drugs 47 (suppl 4): 14–24

    Article  PubMed  Google Scholar 

  60. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I (1979) Prolongation of survival in congestive cardiomyopathy by beat-receptor blockade. Lancet 1: 1374–1376

    Article  PubMed  CAS  Google Scholar 

  61. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I (1980) Adverse effects of beta-blocker withdrawal in patients with congestive cardiomyopathy. Br Heart J 44: 134–142

    Article  PubMed  CAS  Google Scholar 

  62. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I (1980) Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 44: 117–133

    Article  PubMed  CAS  Google Scholar 

  63. Sung C-P, Arleth AJ, Ohlstein EH (1993) Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 21: 221–227

    Article  PubMed  CAS  Google Scholar 

  64. Sutton MSJ, Pfeffer MA, Plappert T et al. (1994) Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. Circulation 89: 68–75

    Google Scholar 

  65. Ungerer M, Böhm M, Elce JS, Erdmann E, Lohse MJ (1993) Altered expression of β-adrenergic receptor kinase and β 1-adrenergic receptors in the failing human heart. Circulation 87: 454–463

    PubMed  CAS  Google Scholar 

  66. Waagstein F, Bristow MR, Swedberg K et al. (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342: 1441–1446

    Article  PubMed  CAS  Google Scholar 

  67. Waagstein F, Caidahl K, Wallentin I et al. (1989) Long-term beta-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 80: 551–563

    Article  PubMed  CAS  Google Scholar 

  68. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I (1975) Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37: 1022–1036

    Article  PubMed  CAS  Google Scholar 

  69. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ (1987) Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76: 44–51

    Article  PubMed  CAS  Google Scholar 

  70. White M, Yanowitz F, Gilbert EM et al. (1995) Role of β-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilative cardiomyopathy. Am J Cardiol 76: 1271–1276

    Article  PubMed  CAS  Google Scholar 

  71. Whyte K, Jones CR, Howie CA et al. (1987) Haemodynamic metabolic and lymphocyte beta2-adrenoceptor changes following chronic beta-adrenoceptor antagonism. Eur J Clin Pharmacol 32: 237–243

    Article  PubMed  CAS  Google Scholar 

  72. Yoshikawa T, Port JD, Asaro K, Bristow MR et al. (1996) Cardiac adrenergic receptor effects of Carvedilol. Eur Heart J 17 (Suppl B): 8–16

    PubMed  CAS  Google Scholar 

  73. Yue TL, Cheng H-J, Lysko PG et al. (1992) Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263: 92–98

    PubMed  CAS  Google Scholar 

  74. Yue T-L, Liu T, Feuerstein G (1992) Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, inhibits oxygen radical mediated lipid peroxidation in swine ventricular membranes. Pharmacol Communications 1 : 27–35

    CAS  Google Scholar 

  75. Yue TL, Ma XL, Wang X, Romanic AM, Liu G-L, Louden C, Gu J-L, Kumar S, Poste G, Ruffolo RR, Feuerstein GZ (1998) Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by Carvedilol. Circ Res 82: 166–174

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innere Medizin III, Medizinische Universitätsklinik und Poliklinik, 66421, Homburg/Saar, Germany

    Dr. Christoph Maack & Prof. Dr. Michael Böhm

Authors
  1. Dr. Christoph Maack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Michael Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Kardiologie und Pneumologie, Universität Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Germany

    G. Hasenfuss

  2. Medizinische Fakultät, Ethik Kommission, Elsässer Straße 2a, Haus 1a, 79110, Freiburg, Germany

    H. Just

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Steinkopff Verlag Darmstadt

About this paper

Cite this paper

Maack, C., Böhm, M. (2000). β-Blocker treatment of chronic heart failure with special regard to Carvedilol. In: Hasenfuss, G., Just, H. (eds) Heart rate as a determinant of cardiac function. Steinkopff. https://doi.org/10.1007/978-3-642-47070-7_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-47070-7_20

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-642-47072-1

  • Online ISBN: 978-3-642-47070-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation